LOS ANGELES, Feb. 3, 2014 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced that Andrew Gengos, Chief
Executive Officer, will present a corporate overview and business
update at the 16th Annual BIO CEO & Investor
Conference at 1:30 pm ET on
Monday, February 10, 2014, at the
Waldorf Astoria Hotel in New York
City.
(Logo:
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO)
To access the live audio webcast of the BioCentury NewsMakers
presentation, please log on through a link located in the Investors
section of ImmunoCellular's website at www.imuc.com, under the
Events & Presentations tab. A replay of the webcast will be
available one hour after the conclusion of the live event.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based clinical-stage company
that is developing immune-based therapies for the treatment of
brain and other cancers. ImmunoCellular has concluded a phase II
trial of its lead product candidate, ICT-107, a dendritic
cell-based vaccine targeting multiple tumor-associated antigens for
glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a
dendritic cell vaccine targeting CD133, and ICT-140, a dendritic
cell vaccine targeting ovarian cancer antigens and cancer stem
cells. To learn more about ImmunoCellular, please visit
www.imuc.com.
Contact:
For ImmunoCellular Therapeutics, Ltd.
Jane Green.
Investor Relations
415.348.0010
jane@jmgcomm.com
SOURCE ImmunoCellular Therapeutics, Ltd.